Results 121 to 130 of about 235,698 (344)

Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki, Kyriakos Dimitriadis, Nikolaos Pyrpyris, Georgios Tzimas, Ioannis Skalidis, David Meier, Panagiotis Antiochos, Panagiotis Kostakis, Efthymia Pavlou, Francesco Perone, Georgios Tsivgoulis, Constantina Aggeli, Ole de Backer, Konstantinos Tsioufis   +13 more
wiley   +1 more source

Anticoagulation therapy could improve the restoration of sinus rhythm and spontaneous circulation in hospital patients with CPR

Journal of International Medical Research, 2019
Objective To analyse the role of anticoagulation therapy in cardiopulmonary resuscitation (CPR) following an in-hospital cardiac arrest. Methods This single-centre retrospective cohort study enrolled patients treated with in-hospital CPR that met the ...
Hai Wang, Zheng-Hai Bai, Jun-Hua Lv, Jiang-Li Sun, Yu Shi, Hong-Hong Pei, Zheng-Liang Zhang   +6 more
doaj   +1 more source

Portal vein thrombosis : a case report and literature review [PDF]

, 2013
A case report of Portal Vein Thrombosis (PVT) as a complication of protein S deficiency. PVT has been increasingly diagnosed over the years, particularly through the use of ultrasound-Doppler equipment.
Cuschieri, Sarah, Gauci, James, Vassallo, Mario   +2 more
core  

Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort [PDF]

, 2017
Aims: To examine the number and type of co-morbid long-term health conditions (LTCs) and their associations with all-cause mortality in an atrial fibrillation (AF) population.
Connelly, Derek T., Gallacher, Katie I., Hanlon, Peter, Jani, Bhautesh Dinesh, Lee, Duncan, Mair, Frances S., McQueenie, Ross, Nicholl, Barbara I.   +7 more
core   +1 more source

Impact of Heart Failure and Chronic Kidney Disease on All‐Cause Mortality in Patients Undergoing Coronary Angiography: Results From the Finnish Kardio Multicentre Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Heart failure (HF) and chronic kidney disease (CKD) are common comorbidities among patients undergoing coronary angiography. Both conditions are associated with increased risk of adverse cardiovascular outcomes and mortality. However, the joint prognostic impact of HF and CKD in this patient population remains unclear. Aims We aimed
Jari A. Laukkanen, Jaakko Immonen, Jussi Hernesniemi, Mari Merentie, Ashish H. Shah, Markku Eskola, Sudhir Kurl, Setor K. Kunutsor   +7 more
wiley   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

, 2015
Peer reviewedPublisher ...
Counsell, Carl, Kane, Edward J, Sandercock, Peter A G   +2 more
core   +1 more source

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

Clinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson, D. Max Smith, Sony Tuteja, Jai N. Patel, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +4 more
wiley   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline [PDF]

, 2016
The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular & Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to assist physical therapists in their decision-making process when ...
Auten, Beth, Frese, Ethel M., Hillegass, Ellen, Puthoff, Michael, Sobush, Dennis, Thigpen, Mary   +5 more
core   +1 more source

MONITORING ANTICOAGULATION AND REVERSAL - EFFECT ON BLOOD LOSS [PDF]

, 1979
David R. Jobes, Alan Jay Schwartz, Norig Ellison, R. Andrews, R Ruffini, J. Ruffini   +5 more
openalex   +1 more source